Mereo BioPharma Group plc (NASDAQ:MREO) is expected to report second quarter earnings results, before market open, on Tuesday 29th September 2020.
Stock Performance
Shares of Mereo BioPharma Group plc traded low $ -0.05 or -1.91 percent on Monday, reaching $ 2.57 with volume of 87.80 thousand shares. Mereo BioPharma Group plc has traded high as $ 2.69 and has cracked $ 2.50 on the downward trend
According to the previous trading day, closing price of $ 2.57, representing a 279.71 % increase from the 52 week low of $ 0.69 and a 38.35 % decrease over the 52 week high of $ 4.25.
The company has a market capital of $ 192.82 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Mereo BioPharma Group plc will be hosting a conference call at 8:00 AM eastern time on 29th September 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.mereobiopharma.com
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. The company also develops OMP-305B83 and OMP-313M32, which are anti-cancer therapeutic candidates in clinical development stage.
